Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15546090.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed. Initial response was achieved in 25 patients (64%), including 16 patients (43%) with initial parasitological cure. Repeated responses after relapse and tolerability of long courses of treatment indicate the potential for development of optimized dosage schemes.
Medical subject headings
- Antiprotozoal Agents
- HIV Infections
- Leishmaniasis
- Phosphorylcholine